Summary
Cystatin C (CyC) is a secreted cysteine protease inhibitor and its biological functions remain insufficiently characterized. Plasma CyC is elevated in many patients, especially when receiving glucocorticoid (GC) treatment. Endogenous GCs are essential for life and are appropriately upregulated in response to systemic stress. Here we empirically connect GCs with systemic regulation of CyC. We used genome-wide association and structural equation modeling to determine the genetics of the latent trait CyC production in UK Biobank. CyC production and a polygenic score (PGS) capturing germline predisposition to CyC production predicted elevated all-cause and cancer-specific mortality. We then demonstrated that CyC is a direct target of GC receptor, with GC-responsive CyC secretion exhibited by macrophages and cancer cells. Using isogenic CyC-knockout tumors, we discovered a markedly attenuated tumor growth in vivo and found abrogated recruitment of Trem2+ macrophages, which have been previously linked to failure of cancer immunotherapy. Finally, we showed that the CyC-production PGS predicted checkpoint immunotherapy failure in a combined clinical trial cohort of 685 metastatic cancer patients. Taken together, our results demonstrate that CyC may be a direct effector of GC-induced immunosuppression, acting through recruitment of Trem2+ macrophages, and therefore could be a target for combination cancer immunotherapy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
T.J. acknowledges funding from Cold Spring Harbor Laboratory and grants from the Simons Foundation, Mark Foundation (20-028-EDV), and Nancy Gay Foundation (58391101). HVM receives funding from the Simons Center for Quantitative Biology at Cold Spring Harbor Laboratory. S.K. was supported by the Starr Centennial Scholarship at the Cold Spring Harbor Laboratory School of Biological Sciences. M.F. is supported by the la Caixa Foundation (ID 100010434) in the framework of the La Caixa Fellowship Program under agreement LCF/BQ/AA18/11680037. B.R.W. is supported by a Wellcome Investigator Award (107049/Z/15/Z). S.B. was supported by a Medical Research Council PhD studentship. Computational analyses were performed with assistance from the US National Institutes of Health Grant S10OD028632-01. L.G.N.A. received Alberta Innovates and Killam doctoral scholarships. S.S. received CIHR Vanier, Alberta Innovates and Killam doctoral scholarships. GJ acknowledges funding from Swedish Research Council (Project 2015-02561 and 2019-01112). Histological processing was performed by the CSHL Tissue Imaging Shared Facility with assistance from the Cancer Center Support Grant 5P30CA045508
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data access relating to this manuscript was approved by the institutional review board (IRB) at Cold Spring Harbor Laboratory, which determined that this work does not meet the definition of human subject research under the purview of the IRB according to federal regulations. This work was reviewed and approved by UK Biobank (application 58510), for details see the UKB ethics and governance framework: https://www.ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵+ Denotes equal contribution
Characterization of CyC knockout isogenic tumor model (Figure 6, Figure S7)
Data Availability
Due to the data use agreements for the datasets analyzed in this manuscript, we are unable to directly share or distribute any patient-level data except for COVID-19 patient scRNA-seq (reposited at https://doi.org/10.6084/m9.figshare.14330795.v13, filename 'covid.combined_final.CD14.Mono.Robj'). All summary statistics are published alongside the study, and polygenic scores will be reposited on PGS Catalog on the acceptance of the peer-reviewed manuscript. To facilitate dataset requests from applicable data use committees, we provide all accession codes for all datasets relating to this manuscript in the Methods and in Table S1. UK Biobank data can be requested through the application process detailed at https://www.ukbiobank.ac.uk/. Single-cell RNA sequencing from mouse tumors will be deposited on SRA on acceptance of a peer-reviewed manuscript, the processed Seurat matrix is available from Figshare (https://doi.org/10.6084/m9.figshare.20063402). Primary data for in vitro and in vivo experiments will be published on acceptance of a peer-reviewed manuscript. All scanned slides will be made available through the CSHL data repository on acceptance of a peer-reviewed manuscript. Code to reproduce core computational and statistical analyses has been reposited on Github at https://github.com/Janowitz-Lab/cystatinc. Where data use agreements allow, additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.